A citation-based method for searching scientific literature




Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville, Karl M Thorpe, John J V McMurray, Stefano Del Prato. Lancet 2018
Times Cited: 607




List of shared articles



Times cited

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Michael A Nauck, Daniel R Quast, Jakob Wefers, Juris J Meier. Mol Metab 2021
34

Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
1

From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A Leiter, Antonio Ceriello, Ralph A DeFronzo, Itamar Raz. Cardiovasc Diabetol 2021
3

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
Emily Brown, Hiddo J L Heerspink, Daniel J Cuthbertson, John P H Wilding. Lancet 2021
3

0

Incretin therapy for diabetes mellitus type 2.
Jens Juul Holst. Curr Opin Endocrinol Diabetes Obes 2020
9

Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
Lawrence Blonde, Lidia Belousova, Udi Fainberg, Pedro A Garcia-Hernandez, Sunil M Jain, Margit S Kaltoft, Ofri Mosenzon, Jalal Nafach, Mads Sundby Palle, Rosangela Rea. Diabetes Obes Metab 2020
13

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data.
Richard A Chudleigh, Julia Platts, Stephen C Bain. Diabetes Metab Syndr Obes 2020
7


Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
Annemarie B van der Aart-van der Beek, Daniel H van Raalte, Cristian Guja, Klaas Hoogenberg, Lisa J Suchower, Elise Hardy, C David Sjöström, Hiddo J L Heerspink. Diabetes Obes Metab 2020
7



2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, James L Januzzi, Rita R Kalyani, Mikhail Kosiborod, Melissa Magwire, Pamela B Morris, Joshua J Neumiller,[...]. J Am Coll Cardiol 2020
58

Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.
Christoffer Clemmensen, Brian Finan, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp, Susanna M Hofmann. Nat Rev Endocrinol 2019
44

New pharmacological strategies for protecting kidney function in type 2 diabetes.
Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. Lancet Diabetes Endocrinol 2019
29

The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.
Sebastian M Heimbürger, Andreas Brønden, Nicklas J Johansen, Thomas F Dejgaard, Tina Vilsbøll, Filip K Knop. Expert Opin Pharmacother 2019
7